ClinicalTrials.gg
CompletedNCT07015125Updated Oct 30, 2025

Evaluation of a Wearable Device for Acute Treatment of Migraines

An interventional study of Transcutaneous Electrical Nerve Stimulation (TENS) in Migraine, Migraine With or Without Aura and Migraine, Acute, sponsored by Hinge Health, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Hinge Health, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
223rd of 610
160 · median 78
Started
2025
with 31 others
No phase
204 of 697
31 open now
Registered
649th of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 223rd largest by enrollment of the 610 interventional ones that give a count, is one of 32 that started in 2025, is one of 204 with no phase, and was the 649th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the efficacy of a new, improved neuromodulation device that can be worn on the head and neck to relieve migraine pain. To measure efficacy, investigators will compare how measured outcomes resulting from active stimulation with this device compare to those of sham treatment.

Read the detailed description

The objective of this study is to examine the extent to which a transcutaneous electrical nerve stimulation (TENS) device safely helps participants with acute migraines reduce migraine pain intensity, achieve pain freedom, and experience sustained pain freedom. The TENS device attaches to a gel pad that can be worn in one of three placement locations to stimulate sensory nerves implicated in migraine pain. The TENS device outputs two active electrical waveforms that differ in stimulation intensity but can both be used to address migraine pain through a 1-hour treatment session. To achieve the study objective, investigators will perform a randomized controlled trial (RCT) with a 3x3 factorial design in which participants will be randomized across the 3 TENS device placement options and each participant will test 3 waveforms: two active waveforms and a sham waveform. Each waveform will be used in a distinct migraine episode. The investigators will evaluate the study aims for each active treatment (six in total) compared to its corresponding sham.

03

Conditions studied

  • Migraine
  • Migraine With or Without Aura
  • Migraine, Acute
  • Migraine Headache

Keywords

  • Migraines
  • Acute Migraines
  • Headaches
  • Pain
  • Chronic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of migraine with or without aura, identified via participant-provided medical records.
  • Average migraine pain is 4 or more on the 0-10 Numerical Rating Scale (NRS) for pain.
  • Passes ID-Migraine pre-screening questions and has ID-Migraine score ≥ 2:

    a. ID-Migraine pre-screening questions: i. How many headaches have participants experienced within the previous 3 months?

  • Needs to be ≥ 6 headaches ii. Do the headaches that participants experience limit the ability to work, study, or enjoy life, or does the participant wish to speak with a healthcare professional about the headaches? (yes / no)
  • Participant needs to respond "yes" b. ID-Migraine questions: i. Over the last 3 months, did participants have any of the following with headaches?
  • Felt nauseated or sick to stomach (yes [1] / no [0])
  • Light bothered them (a lot more than when headaches are not present)? (yes [1] / no [0])
  • Headaches limited the ability to work, study, or do what needed to be done? (yes [1] / no [0])
  • Able to understand and provide .
  • Age 18 and older.
  • US resident.
  • Has experienced migraines for at least 1 year prior to recruitment.
  • Onset of migraines occurred at age 50 years or younger.
  • Average of at least 2 migraines per month of moderate to severe intensity.
  • Is either on a) no medications or b) a stable dose of migraine-preventative medication for at least 2 months prior to recruitment.
  • Willing to refrain from altering preventive medication for migraines (or from using botox), commit to using Enso as the treatment, and wait at least 2 hours after Enso treatment before using any additional abortives during the study period.
  • Participants must own an iPhone with iOS 15 or newer, or an Android phone with Android 9 or newer, with Bluetooth capability and access to either the Apple App Store (for iOS devices) or Google Play Store (for Android devices).
  • Has an email account.

Exclusion criteria

Exclusion Criteria:

  • Typical migraine pain is \< 4 out of 10 on the 0-10 NRS.
  • Currently institutionalized.
  • Currently is or has ever been a Hinge Health member.
  • Use of antipsychotic medication up to 3 months before study recruitment.
  • Diagnosis of cancer/malignant tumors in the last 5 years.
  • Cognitive, behavioral, neurologic, or psychiatric disorder (e.g., dementia, Parkinson's, schizophrenia, stroke) that may interfere with the study or prevent the subject from complying with the requirements of the protocol.
  • Has epilepsy.
  • Has a history of major cardiovascular events such as strokes, arrhythmias, or myocardial infarction.
  • Has a history of major migraine complications such as migrainous infarction or migraine aura-triggered seizure
  • Diagnosed with secondary headache disorders including medication overuse headaches
  • History of opioid, alcohol, or drug abuse in the last 1 year.
  • Has a cardiac pacemaker, implanted defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other implanted electronic device.
  • Has a metal implant in the upper extremities or head.
  • Has a history of major head or neck surgeries.
  • Pregnant.
  • Currently participating or has participated in a study with an compound or device within the last 30 days before the screening visit.
  • Currently using a TENS device to treat migraines.
  • Received supraorbital nerve blocks or Botox treatment within 4 months prior to recruitment.
  • Insufficient proficiency with the English language to take part in study procedures or complete online surveys.
  • Planning to travel outside of the US within three months after consenting to the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Center of Forehead

    Participants will use the TENS device on the center of the forehead. Participants use 2 active and 1 sham waveform in a randomized order to treat 3 distinct migraine episodes.

    Device: Transcutaneous Electrical Nerve Stimulation (TENS)

  • Experimental
    Side of Forehead

    Participants will use the TENS device on the side of the forehead. Participants use 2 active and 1 sham waveform in a randomized order to treat 3 distinct migraine episodes.

    Device: Transcutaneous Electrical Nerve Stimulation (TENS)

  • Experimental
    Back of Neck

    Participants will use the TENS device on the back of the neck. Participants use 2 active and 1 sham waveform in a randomized order to treat 3 distinct migraine episodes.

    Device: Transcutaneous Electrical Nerve Stimulation (TENS)

Interventions

  • DeviceTranscutaneous Electrical Nerve Stimulation (TENS)

    Use of TENS device for 1 hour during each migraine episode.

    Also known as: Enso

06

What researchers measure

Primary outcomes

  1. Safety/Adverse Events

    Safety will be measured by comparing the number of reportable adverse events, with particular focus on serious adverse events, that occur for the 6 active treatments versus the corresponding sham. Adverse events will be assessed by asking participants of any symptoms or medical issues experienced since the last interaction or activity in the study. Participants will report details of the event, its circumstances, the severity, and outcome/resolution of the event in the post-treatment surveys. The events will be adjudicated by the Study Physician, who will determine seriousness, relatedness and reportability.

    Time frame: Pre-treatment, 1, 2, and 24 hours post-treatment.

  2. Pain Relief at 1 hour (Clinical Efficacy)

    Pain relief will be measured by asking participants to report pain intensity using the 11-point Numeric Rating Scale (NRS) in the pre-treatment survey and in the post-treatment survey 1 hour after the initiation of treatment. NRS pain levels will be converted into categorical ratings of pain severity according to the following mapping between NRS and a 4-point Likert scale: (0-1 NRS =\> no pain; 2-3 NRS =\> mild pain; 4-6 NRS =\> moderate pain; 7-10 NRS =\> severe pain). Pain relief constitutes a change in pain level from severe or moderate pain to mild or no pain. The percentage of participants who achieve pain relief in the active and sham treatments will be compared. Six comparisons will be performed in total, for the 6 active treatments (3 placements x 2 active waveforms).

    Time frame: Pre-treatment, 1-hour post-treatment

Secondary outcomes

  1. Pain Relief at 2 hours

    Pain relief will be measured by asking participants to report pain intensity using the 11-point Numeric Rating Scale (NRS) in the pre-treatment survey and in the post-treatment survey 2 hours after the initiation of treatment. NRS pain levels will be converted into categorical ratings of pain severity according to the following mapping between NRS and a 4-point Likert scale: (0-1 NRS =\> no pain; 2-3 NRS =\> mild pain; 4-6 NRS =\> moderate pain; 7-10 NRS =\> severe pain). Pain relief constitutes a change in pain level from severe or moderate pain to mild or no pain. The percentage of participants who achieve pain relief in the active and sham treatments will be compared. Six comparisons will be performed in total, for the 6 active treatments (3 placements x 2 active waveforms).

    Time frame: Pre-treatment, 2 hours post-treatment

  2. Pain Freedom at 2 hours

    Pain freedom will be defined as a reduction in pain severity from mild, moderate, or severe at baseline to none at 2 hours, using the Numeric Rating Scale (NRS) mapped to a 4-point Likert scale, as based on literature. Six comparisons will be performed in total, for the 6 active treatments (3 placements x 2 active waveforms) vs the corresponding sham.

    Time frame: Pre-treatment, 1, 2 hours post-treatment.

  3. Sustained Pain Freedom

    Sustained pain freedom is defined as pain freedom at 24 hours without the use of anti-migraine medication or relapse during those 24 hours. Sustained pain freedom at 24 hours will be measured using the same four point Likert scale as used to measure pain freedom at 2 hours. Six comparisons will be performed in total, for the 6 active treatments (3 placements x 2 active waveforms) vs the corresponding sham.

    Time frame: 24-hours post-treatment.

07

Study locations

1 site
  • Hinge Health, Inc.
    San Francisco, California 94105, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2025, 3 months.

Of 50 industry-sponsored interventional studies with no phase under Migraine Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's 3 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 11, 2025
StartActual
Jun 9, 2025
Primary completionActual
Sep 24, 2025
CompletionActual
Sep 24, 2025
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07015125
Lead sponsor
Hinge Health, Inc
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 9, 2025
Primary completion
Sep 24, 2025
Completion
Sep 24, 2025
Last update
Oct 30, 2025

Study contacts

Mallika Bariya, PhD
principal investigator · Hinge Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion